Home›Deferiprone›Deferiprone + Antacids Containing Aluminum

Does Deferiprone Interact with Antacids Containing Aluminum?

CDI records a moderate classification for Deferiprone and Antacids Containing Aluminum. The stored summary is: Polyvalent cation that may bind deferiprone. Allow at least 4-hour interval between administration. The mechanism involves binding of polyvalent cations to deferiprone. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.

Stored CDI classification
Moderate
Deferiprone Class
Iron Chelator
Management
Confirm exact products with your pharmacist
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

Binding of polyvalent cations to deferiprone

What To Tell Your Doctor or Pharmacist

If you are taking Deferiprone and your doctor is considering prescribing Antacids Containing Aluminum (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Deferiprone(Ferriprox)+💊 Antacids Containing Aluminum

Severity & Interaction Details

🟡
moderate
Stored CDI classification: moderate
A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.
Severity scale
MinorContra
On record
Yes
Drug A class
Iron Chelator
Drug B class
—
Source
NLP:deferiprone

What this means in plain English

Polyvalent cation that may bind deferiprone. Allow at least 4-hour interval between administration.

About Deferiprone and Antacids Containing Aluminum

Deferiprone is an Iron Chelator. Deferiprone is also sold under the brand name Ferriprox. Deferiprone additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:deferiprone

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Deferiprone and Antacids Containing Aluminum against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations